Embecta Trims FY25 Revenue Outlook - Update

(RTTNews) - While reporting financial results for the second quarter on Friday, diabetes management company Embecta Corp. (EMBC), which was spun-off from medical technology company Becton, Dickinson and Co. (BDX), maintained its adjusted earnings guidance for the full-year 2025, while trimming annual revenue outlook.

For fiscal 2025, the company continues to project adjusted earnings in a range of $2.70 to $2.90 per share. Revenues are now expected revenues between $1.073 billion and $1.090 billion, down from the prior forecast between $1.075 billion and $1.092 billion.

On average, analysts polled expect the company to report earnings of $2.82 per share on revenues of $1.09 billion for the year. Analysts' estimates typically exclude special items.

The Company's Board of Directors also declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock, payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com